The Indian Weekender, 11 June 2021
Weekly Kiwi-Indian publication printed and distributed free every Friday in Auckland, New Zealand
Weekly Kiwi-Indian publication printed and distributed free every Friday in Auckland, New Zealand
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
14<br />
INDIA<br />
Friday, <strong>June</strong> <strong>11</strong>, <strong>2021</strong> <strong>The</strong> <strong>Indian</strong> <strong>Weekender</strong><br />
NEWS in BRIEF<br />
Cheetah: <strong>The</strong> world's fastest cat is returning<br />
to India<br />
If all goes well,<br />
eight cheetahs<br />
- five males and<br />
three females - will<br />
make the 8,405km<br />
(5,222 miles) journey from South Africa to their new home in<br />
a sprawling national park in India in November. <strong>The</strong> world's<br />
fastest land animal will make a comeback in India, more than<br />
half a century after it became extinct in the country.<br />
"Finally we have the resources and the habitat to reintroduce<br />
the cat," says Yadvendradev Jhala, dean of the Wildlife Institute<br />
of India, and one of the experts tasked with the effort. This is<br />
the first time in the world, he says, when a large carnivore will<br />
be relocated from one continent to another for conservation.<br />
With their black spotted coats and teardrop marks, the<br />
cheetah is a sleek animal, racing across grasslands at speeds<br />
touching 70 miles (<strong>11</strong>2km) an hour to capture prey. <strong>The</strong> cat is<br />
also a remarkably athletic animal, braking, ducking and diving<br />
as it goes for the kill.<br />
<strong>The</strong> vast majority of the 7,000 cheetahs in the world are now<br />
found in South Africa, Namibia and Botswana. <strong>The</strong> endangered<br />
cat was reportedly last sighted in India in 1967-68, but their<br />
numbers had vastly dwindled by 1900.<br />
Coronavirus: <strong>The</strong> 'unknown' Covid-19<br />
deaths in rural India<br />
<strong>The</strong> second wave of Covid-19 ravaged India as hospitals<br />
and then crematoriums ran out of space.<br />
Families struggled to find beds, oxygen or even medicines<br />
to save their loved ones. While cities were first hit, the second<br />
wave soon reached rural parts of the country.<br />
Hundreds died due to poor or no access to good healthcare.<br />
Most of them were not even able to get a Covid test done.<br />
Now experts believe that the number of deaths in rural India<br />
is much higher than official statistics.<br />
India's cumulative Covid-19 vaccine<br />
coverage crosses 240 million-mark<br />
<strong>The</strong> number of Covid-19<br />
vaccine doses administered<br />
in the country has crossed 24<br />
crore, the Union Health Ministry<br />
said. <strong>The</strong> ministry said that in<br />
the 18-44 age group, 19,24,924<br />
beneficiaries received the first<br />
dose of vaccine and 86,450 got<br />
the second dose on Wednesday.<br />
So far, 3,38,08,845 people in the 18-44 age group have<br />
received the first dose across states and union territories and<br />
4,05,<strong>11</strong>4 have got the second dose.<br />
Bihar, Delhi, Gujarat, Haryana, Karnataka, Madhya Pradesh,<br />
Maharashtra, Rajasthan, Tamil Nadu, Telangana, Uttar Pradesh<br />
and West Bengal have administered the first dose to more<br />
than 10 lakh beneficiaries in the 18-44 age group each, the<br />
ministry said. <strong>The</strong> country has administered cumulatively<br />
24,24,79,167 vaccine doses, according to a provisional report<br />
at 7 pm on Wednesday.<br />
Covaxin effective in neutralising Delta, Beta<br />
variants of Covid-19: Study<br />
Researchers at Pune’s<br />
<strong>Indian</strong> Council of<br />
Medical Research-National<br />
Institute of Virology<br />
(ICMR-NIV) found that<br />
Bharat Biotech’s Covaxin<br />
is effective in neutralizing<br />
the Delta (B.1.617.2) and<br />
Beta (B.1.351) variants of SARS-CoV-2, which causes the<br />
coronavirus disease (Covid-19).<br />
<strong>The</strong> paper, which is yet to be peer-reviewed, is titled -<br />
“Neutralization against B.1.351 and B.1.617.2 with sera of<br />
COVID-19 recovered cases and vaccinees of BBV152”<br />
- and has been authored by <strong>Indian</strong> Council of Medical<br />
Research (ICMR), the ICMR-NIV and Bharat Biotech.<br />
“<strong>The</strong> study demonstrated that despite a reduction in<br />
neutralization titers with BBV152 vaccinees sera against<br />
B.1.351 and B.1.617.2, its neutralization potential is well<br />
established,” the study pointed out, claiming that the<br />
vaccine developed by the Hyderabad-based pharmaceutical<br />
company is effective against these two variants which<br />
caused widespread concern among doctors for its increased<br />
severity.<br />
VACCINATION<br />
is important to protect<br />
against a spreading variant first<br />
identified in India, Fauci says<br />
Dr. Anthony Fauci pleaded with the<br />
public Tuesday to get vaccinated,<br />
saying the Delta coronavirus<br />
variant -- the B.1.617.2 variant first<br />
identified in India -- accounts for more<br />
than 6% of the sequenced viruses in the<br />
United States.<br />
<strong>The</strong> variant's spread and dominance<br />
in the United Kingdom, which was first<br />
hit hard by the Alpha variant -- B.1.1.7 --<br />
could spell trouble for the United States if<br />
people don't get vaccinated, Fauci said in<br />
a White House Covid-19 briefing.<br />
"We cannot let that happen in the United<br />
States," Fauci said, adding it's "such a<br />
powerful argument" to get vaccinated.<br />
<strong>The</strong> Delta variant "may be associated<br />
with an increased disease severity, such<br />
as hospitalization risk, compared to (the<br />
Alpha variant, B.1.1.7)," Fauci said.<br />
<strong>The</strong> variant is susceptible to available<br />
two-dose vaccines from Pfizer and<br />
AstraZeneca, he said, but protection from<br />
these vaccines requires following a twodose<br />
schedule.<br />
"<strong>The</strong>re is reduced vaccine effectiveness<br />
in the one dose," said Fauci, who is<br />
the National Institute of Allergy and<br />
Infectious Diseases director. "Three<br />
weeks after one dose, both vaccines, the<br />
(AstraZeneca) and the Pfizer/BioNTech,<br />
were only 33% effective against<br />
symptomatic disease from Delta."<br />
<strong>The</strong>re is not yet a booster vaccine trial<br />
underway specific to the Delta variant,<br />
but variant-specific boosters may be on<br />
the horizon, Fauci said.<br />
A booster may focus on a specific<br />
variant, or the type a person was originally<br />
vaccinated against, he said.<br />
"We are approaching both of those, but<br />
the one thing that we are noticing that's<br />
important is that the higher your degree of<br />
immune response against the wild type,<br />
the greater the secondary coverage you<br />
have against a wide array of variants,"<br />
he said. "You can boost against the wild<br />
type, and still cover variants, including<br />
617."<br />
Vaccination numbers have<br />
plummeted since April<br />
Fauci's plea for Americans to get<br />
vaccinated against Covid-19 comes as<br />
vaccinations across the country have<br />
slowed, leaving unvaccinated Americans<br />
vulnerable to new variants and<br />
threatening the chances of reaching<br />
h e r d<br />
immunity.<br />
Over the last week, the US averaged<br />
more than 1.07 million Covid-19 vaccine<br />
shots administered per day -- well below<br />
the peak seven-day average of 3.38<br />
million shots per day reached on April<br />
13, according to data from the Centers for<br />
Disease Control and Prevention.<br />
Mississippi is the state with the<br />
lowest percentage of its population<br />
fully vaccinated -- 27.5% as of Monday,<br />
according to the CDC.<br />
<strong>The</strong> state fell from 128,841 doses<br />
administered during the week ending<br />
March 27 down to 24,374 doses in the<br />
week ending <strong>June</strong> 5.<br />
Alabama has the second-lowest<br />
percentage of fully vaccinated residents<br />
among all states -- 29.4% as of Monday,<br />
according to CDC data.<br />
<strong>The</strong> state fell from 44,397 doses<br />
administered April 8 down to 1,465 doses<br />
on Saturday, according to the Alabama<br />
Department of Public Health's Covid-19<br />
dashboard.<br />
Arkansas, Louisiana and Tennessee<br />
and Wyoming also had less than 33% of<br />
their populations fully vaccinated as of<br />
Monday.<br />
"I understand that in the short run<br />
we may get away with it, having slow<br />
vaccination rates," said Dr. Ashish Jha,<br />
dean of the Brown University School of<br />
Public Health.<br />
"But those people really are vulnerable<br />
– once we have more variants circulating<br />
in the United States -- to get reinfected<br />
and potentially get very sick."<br />
Even those who've already had<br />
coronavirus should get vaccinated<br />
because research shows immunity<br />
achieved through vaccination is better<br />
than immunity through previous<br />
infection, Fauci said.<br />
"We need to get vaccinated because<br />
vaccines are highly efficacious. <strong>The</strong>y are<br />
better than the traditional response you<br />
get from natural infection," Fauci<br />
said last month.<br />
Lab research shows<br />
those who previously<br />
had Covid-19 and<br />
received two doses of<br />
an mRNA vaccine "had<br />
interesting, increased<br />
protection against<br />
the variants of<br />
concern," he said.<br />
And those<br />
relying on their<br />
immunity from<br />
previous infection<br />
need to understand<br />
the danger of new<br />
variants, Jha said.<br />
"This is a bit of a misunderstanding that<br />
unfortunately a lot of people have ... this<br />
idea that if you've been infected that you<br />
have natural immunity that you don't need<br />
to get vaccinated," Jha said.<br />
"<strong>The</strong>re is no doubt about it in my mind<br />
that a vaccine-induced immunity is much<br />
more durable and is going to hold up<br />
much better against the variants."<br />
Right now, the three vaccines used<br />
in the US work well against known<br />
variants of concern. But as coronavirus<br />
keeps spreading and mutating among<br />
unvaccinated people, "there may be future<br />
variants for which we are not so lucky,"<br />
said emergency physician Dr. Megan<br />
Ranney, director of the Brown-Lifespan<br />
Center for Digital Health.<br />
Rare breakthrough infections<br />
have milder outcomes<br />
While the Moderna, Pfizer/BioNTech<br />
and Johnson & Johnson vaccines are<br />
highly effective at preventing severe<br />
Covid-19, they're not perfect at preventing<br />
infection. But even those who get infected<br />
down the road after getting vaccinated<br />
will likely be less miserable than if they<br />
hadn't gotten vaccinated at all.<br />
CDC data published research showing<br />
those who had rare "breakthrough"<br />
infections after one or two doses of<br />
vaccine had 40% less virus in their bodies<br />
and were 58% less likely to have a fever.<br />
<strong>The</strong>y also spent two fewer days in bed<br />
than unvaccinated Covid-19 patients,<br />
according to the study.<br />
"<strong>The</strong> only way to be protected is to be<br />
fully vaccinated," Jha said.<br />
For those taking the Pfizer/BioNTech<br />
or Moderna vaccines, "This is why<br />
everybody needs a second dose."<br />
Moderna says data on<br />
vaccines for 5-year-olds<br />
likely available in early fall<br />
Moderna anticipates it will have data<br />
on the Covid-19 vaccine for children as<br />
young as 5 in September or October.<br />
"I think it's going to be early fall just<br />
because we have to go down in age very<br />
slowly and carefully," Moderna CEO<br />
Stéphane Bancel said at an event Monday<br />
hosted on the social media platform<br />
Clubhouse.<br />
<strong>The</strong> Pfizer/BioNTech vaccine has<br />
already been approved for children as<br />
young as 12. Moderna said it is testing its<br />
vaccine on children as young as 6 months.<br />
Bancel said the process will take time<br />
as it determines the appropriate dosages<br />
for small children. "We anticipate data<br />
available in the September/October time<br />
frame," he said.